Enzymatica AB (publ) (STO:ENZY)
1.950
-0.100 (-4.88%)
Aug 14, 2026, 5:22 PM CET
Enzymatica AB Earnings Call Transcripts
Fiscal Year 2025
-
Recent independent studies confirm ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, as shown in both athlete-based and cell culture models. The product demonstrated strong efficacy and safety, with results expected to apply to the general population.